Patents by Inventor Aymeric Duclert

Aymeric Duclert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250034641
    Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).
    Type: Application
    Filed: October 14, 2024
    Publication date: January 30, 2025
    Applicant: CELLECTIS
    Inventors: David SOURDIVE, Aymeric DUCLERT, Mathieu SIMON, Philippe DUCHATEAU, Alan Marc WILLIAMS, Laurent POIROT
  • Patent number: 12144825
    Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: November 19, 2024
    Assignee: CELLECTIS
    Inventors: David Sourdive, Aymeric Duclert, Mathieu Simon, Philippe Duchateau, Alan Marc Williams, Laurent Poirot
  • Publication number: 20220233588
    Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).
    Type: Application
    Filed: July 2, 2018
    Publication date: July 28, 2022
    Inventors: David SOURDIVE, Aymeric DUCLERT, Mathieu SIMON, Philippe DUCHATEAU, Alan Marc WILLIAMS, Laurent POIROT
  • Publication number: 20210017545
    Abstract: The present invention relates to the field of genome engineering (gene editing). More specifically the invention provides with allele specific TALE-nucleases and methods to operate allele specific gene repair by homologous recombination in primary cells, such as hematopoietic stem cells, blood cells and hepatocytes. These reagents and methods can be used for the genetic treatment of inherited disease, such as sickle cell disease betathalassemia.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 21, 2021
    Inventors: Alex BOYNE, Brian BUSSER, Philippe DUCHATEAU, Aymeric DUCLERT
  • Patent number: 9290748
    Abstract: The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: March 22, 2016
    Assignee: Cellectis
    Inventors: Olivier Danos, Aymeric Duclert
  • Publication number: 20130227715
    Abstract: The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual.
    Type: Application
    Filed: February 28, 2011
    Publication date: August 29, 2013
    Applicant: CELLECTIS
    Inventors: Olivier Danos, Aymeric Duclert
  • Publication number: 20110239319
    Abstract: The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention further concerns the use of such endonucleases for inserting transgenes into a cell, tissue or individual.
    Type: Application
    Filed: February 28, 2011
    Publication date: September 29, 2011
    Inventors: Olivier DANOS, Aymeric Duclert
  • Patent number: 7393663
    Abstract: The sequences of 5? ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs. The 5? ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5? ESTs. The 5? ESTs may also be used to design expression vectors and secretion vectors.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: July 1, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Bruno Lacroix
  • Patent number: 7235381
    Abstract: The sequences of 5? ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs. The 5? ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5? ESTs. The 5? ESTs may also be used to design expression vectors and secretion vectors.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: June 26, 2007
    Assignee: Serono Genetics Institute S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Jean-Yves Giordano
  • Publication number: 20070027308
    Abstract: The sequences of 5? ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs. The 5? ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be otained using the 5? ESTs. The 5? ESTs may also be used to design expression vectors and secretion vectors.
    Type: Application
    Filed: July 30, 2003
    Publication date: February 1, 2007
    Inventors: Jean-Baptiste Milne Edwards, Aymeric Duclert, Bruno Lacroix
  • Publication number: 20070009941
    Abstract: The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.
    Type: Application
    Filed: June 16, 2006
    Publication date: January 11, 2007
    Applicant: Serono Genetics Institute S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret
  • Publication number: 20060286639
    Abstract: The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.
    Type: Application
    Filed: June 29, 2006
    Publication date: December 21, 2006
    Applicant: SERONO GENETICS INSTITUTE S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Jobert, Catherine Clusel, Aymeric Duclert
  • Patent number: 7122644
    Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: October 17, 2006
    Assignee: Serono Genetics Institute S.A.
    Inventors: Frances Yen-Potin, Blake Denison, Aymeric Duclert, Lydie Bougueleret, Catherine Clusel, Jean-Baptiste Dumas Milne Edwards, Bernard Bihain, Barbara Bour, Dana Ebbets-Reed, Luisa Salter-Cid
  • Publication number: 20060223142
    Abstract: The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.
    Type: Application
    Filed: November 10, 2005
    Publication date: October 5, 2006
    Applicant: Serono Genetics Institute S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret
  • Patent number: 7115416
    Abstract: The sequences of 5? ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs. The 5? ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5? ESTs. The 5? ESTs may also be used to design expression vectors and secretion vectors.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: October 3, 2006
    Assignee: Serono Genetics Institute S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Jean-Yves Giordano
  • Publication number: 20060189793
    Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptdes. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.
    Type: Application
    Filed: April 27, 2006
    Publication date: August 24, 2006
    Applicant: Serono Genetics Institute S.A.
    Inventors: Frances Yen, Blake Denison, Aymeric Duclert, Lydie Bougueleret, Catherine Clusel, Jean-Baptiste Dumas Milne-Edwards, Bernard Bihain, Barbara Bour, Dana Ebbets-Reed, Luisa Salter-Cid
  • Patent number: 7056680
    Abstract: The sequence of a cDNA encoding Claudin-50 and sequence of Claudin-50 protein are disclosed. The cDNA can be used to express the protein or portions thereof or to obtain antibodies capable of specifically binding to the secreted protein. The cDNA may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNA may also be used to design expression vectors and secretion vectors.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: June 6, 2006
    Assignee: Serono Genetics Institute S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret
  • Publication number: 20060009633
    Abstract: The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.
    Type: Application
    Filed: October 15, 2001
    Publication date: January 12, 2006
    Applicant: GENSET, S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Jobert, Catherine Clusel, Aymeric Duclert
  • Patent number: 6936692
    Abstract: The sequences of extended cDNAs encoding secreted proteins are disclosed. The extended cDNAs can be used to express secreted proteins or portions thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The extended cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The extended cDNAs may also be used to design expression vectors and secretion vectors.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: August 30, 2005
    Assignee: Genset, S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret
  • Publication number: 20050106595
    Abstract: The sequences of 5? ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs. The 5? ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5? ESTs. The 5? ESTs may also be used to design expression vectors and secretion vectors.
    Type: Application
    Filed: August 25, 2004
    Publication date: May 19, 2005
    Applicant: Genset S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Jean-Yves Giordano